14 news items
BioNTech Partner Medilink Therapeutics Says FDA Has Placed Partial Clinical Hold On Phase 1 Trial Of BNT326/YL202 For Heavily Pre-Treated Advanced Or Metastatic EGFR-Mutated Non-small Cell Lung Cancer Or HR+/HER2-Negative Breast Cancer-6K
BNTX
17 Jun 24
additional information in the investigators brochure regarding the safety findings including grade 5 adverse events observed in studies YL202-INT-101-01 and YL202-CN-201-01.
.
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BNTX
CTMX
FGEN
3 Jun 24
investigational, masked, conditionally activated PROBODY T-cell engager, CX-904, demonstrating a favorable safety profile and confirmed anti-cancer
Biotech Advances in 2024: Innovative Treatments Aim to Boost Pancreatic Cancer Survival Rates
BNTX
CTMX
FGEN
3 Jun 24
for its investigational, masked, conditionally activated PROBODY T-cell engager, CX-904, demonstrating a favorable safety profile and confirmed anti
Genmab, BioNTech Announced Data At ASCO, Showing Investigational Acasunlimab In Combination With Pembrolizumab Resulted In 12-month Overall Survival Rate of 69% In Patients With Previously Treated Metastatic Non-small Cell Lung Cancer
BNTX
GMAB
2 Jun 24
acasunlimab (DuoBody-PD-L1x4-1BB), an investigational bispecific antibody also known as GEN1046/BNT311, as monotherapy and in combination with pembrolizumab
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)
BNTX
GMAB
1 Jun 24
), an investigational bispecific antibody also known as GEN1046/BNT311, as monotherapy and in combination with pembrolizumab in patients with PD-L(1)-positive
r17lqdog
BNTX
GMAB
1 Jun 24
) evaluating acasunlimab (DuoBody-PD-L1x4-1BB), an investigational
y9gq4j7lwi zj7v52rll
AMGN
BNTX
MRK
24 May 24
investigation of TIL expansion as a potential biomarker of clinical activity in patients treated with pelareorep
kij5ziv33856okb3731 673u1yyx3ubsb8
BNTX
21 May 24
: Updates on several Phase 1b/2a trials investigating BNT327/PM8002 as a monotherapy in patients
hld0cgwcqua3kj4w03mg0jz43lbyrlaqqslnmbez
BNTX
6 May 24
-the-shelf mRNA-based cancer vaccine candidates based on iNeST and FixVac platforms, including three-year follow-up data of an investigator-initiated
csbpb7l qr2ak
BNTX
8 Apr 24
Three-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran
mjf tpvi63p1nfi
BNTX
7 Apr 24
-year follow-up data of an investigator-initiated Phase 1 trial of the individualized mRNA cancer vaccine candidate autogene cevumeran (BNT122
wb3o6328166puhl6asgc7fkx
BNTX
FOLD
GSK
26 Mar 24
agreement with BioNTech SE (NASDAQ:BNTX) for the discovery of investigational
3rhpj0ujom2 0i
BNTX
20 Mar 24
pipeline encompasses multiple candidates in mid- and late-stage clinical development, including investigational ADCs, mRNA vaccines and innovative
hsw50ttokx0b 8aqgx88wyahoc65uo7e53mj79why495w3bhqex3iimcs
BNTX
20 Mar 24
opportunities and discover and develop investigational medicines; the ability and willingness of BioNTech's third-party collaborators to continue
- Prev
- 1
- Next